Agenus to Host March 2026 Stakeholder Webcast Highlighting Progress of BOT + BAL Immunotherapy and Expanding Patient Access Across Multiple Tumor Types
Agenus Inc., a biotechnology company focused on advancing innovative immuno-oncology therapies, has announced that it will host its March Stakeholder Webcast, an event dedicated to providing updates on the company’s clinical progress, strategic priorities, and patient access initiatives. The session will place particular emphasis on the continued advancement of its botensilimab and balstilimab (BOT+BAL) combination immunotherapy program, which remains central to Agenus’ oncology pipeline.
The upcoming webcast represents an important opportunity for investors, clinicians, and other stakeholders to gain deeper insights into the company’s evolving strategy and development efforts. Agenus has positioned BOT+BAL as a potentially transformative immunotherapy combination designed to address unmet needs across a range of tumor types, including those that have historically shown resistance to existing immunotherapy approaches.
The session will be moderated by Garo H. Armen, Founder, Chairman, and Chief Executive Officer of Agenus, who will guide the discussion and provide opening remarks. The event will conclude with a live question-and-answer segment, allowing participants to engage directly with company leadership and gain clarity on key topics.
Dr. Armen is expected to begin the webcast by outlining Agenus’ broader mission to harness the power of the immune system to treat cancer. He will emphasize the company’s commitment to expanding the reach of immunotherapy across multiple tumor types, particularly in cancers where treatment options remain limited and outcomes are often poor. His remarks will also include an overview of the company’s strategic priorities for 2026, reflecting the momentum that Agenus has built in advancing its BOT+BAL program through clinical development.
A central theme of the discussion will be the progress of the BOT+BAL combination, which pairs botensilimab, a next-generation CTLA-4 inhibitor, with balstilimab, a PD-1 blocking antibody. This dual checkpoint inhibition strategy is designed to enhance immune activation against tumors while potentially improving efficacy in patient populations that do not respond adequately to conventional therapies. The combination is being evaluated across multiple tumor types, with a particular focus on cancers that have demonstrated resistance to earlier immunotherapy regimens.
Providing a clinical perspective during the webcast will be Steven J. O’Day, Chief Medical Officer of Agenus. Dr. O’Day will discuss emerging data related to the durability and consistency of responses observed with BOT+BAL across different cancer indications. His presentation is expected to highlight how the combination has performed in both immunotherapy-sensitive and immunotherapy-resistant tumors, offering insights into its potential to broaden the applicability of checkpoint blockade strategies.
In addition to reviewing clinical outcomes, Dr. O’Day will address how these findings are shaping the company’s ongoing development plans. This includes informing the design of later-stage clinical trials, optimizing patient selection strategies, and identifying tumor types where the combination may deliver the greatest clinical benefit. Such insights are critical as Agenus seeks to transition its program into more advanced stages of development and ultimately toward potential regulatory submissions.
Another key component of the webcast will focus on patient access and the company’s efforts to expand availability of its investigational therapies to individuals with limited treatment options. Kamel Djazouli, Head of Medical Affairs at Agenus, will provide an update on global access programs that are currently in place. These include initiatives such as the French Autorisation d’Accès Compassionnel (AAC) program and Named Patient Programs, which allow eligible patients to receive investigational treatments outside of formal clinical trials.
Dr. Djazouli’s discussion will underscore the importance of these programs in bridging the gap between clinical development and broader regulatory approval. For patients with advanced or refractory cancers who have exhausted standard treatment options, such access pathways can offer a critical lifeline, enabling them to benefit from emerging therapies while additional clinical data are being generated.
The webcast will also serve as a platform to review Agenus’ execution strategy, including how the company is coordinating clinical development, regulatory engagement, and patient access initiatives on a global scale. By aligning these efforts, Agenus aims to accelerate the delivery of its therapies to patients while maintaining a strong focus on scientific rigor and clinical evidence generation.
Participants interested in attending the webcast will be required to register in advance, after which they will receive access to the live streaming link. The company has also provided an option for stakeholders to submit questions ahead of the event, ensuring that key areas of interest can be addressed during the live Q&A session.
This March Stakeholder Webcast marks the second installment in Agenus’ 2026 Stakeholder Briefing Series. The series is designed to provide regular updates on the company’s progress, building on earlier discussions that have covered topics such as clinical data from the BOT+BAL program, advancements in patient access pathways, and broader corporate developments.
Overall, the upcoming session reflects Agenus’ commitment to transparency and engagement with its stakeholders, as well as its determination to advance innovative immuno-oncology solutions. As the company continues to generate clinical evidence and expand its programs, events like this webcast play a crucial role in communicating progress and maintaining momentum.
With continued focus on scientific innovation, patient access, and strategic execution, Agenus is positioning itself to play a meaningful role in the future of cancer treatment. The BOT+BAL program, in particular, represents a cornerstone of this effort, with the potential to redefine how immunotherapy is applied across a diverse range of tumor types.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants.
Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.
About Botensilimab (BOT)
Botensilimab is a multifunctional, human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to “cold” tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.
Botensilimab alone, or in combination with Agenus’ investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. Approximately 1,200 patients have been treated across the botensilimab/balstilimab program in phase 1 and phase 2 clinical trials. For more information about botensilimab trials, visit www.clinicaltrials.gov.
About Balstilimab (BAL)
Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in >900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.
Source Link:https://www.businesswire.com/
